BioMarin Pharmaceutical (BMRN) AI Stock Analysis

• Market Cap: $10.58B
• Dividend Yield: N/A
• Average Volume (3M): 2.25M
• Price to Earnings (P/E): 20.4
• Beta (1Y): 0.40
• Revenue Growth: 17.99%
• EPS Growth: 152.10%
• Country: US
• Employees: 3,040
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): 0.95
• Shares Outstanding: 191,775,670
• 10 Day Avg. Volume: 2,286,366
• 30 Day Avg. Volume: 2,246,354
• PEG Ratio: 0.90
• Price to Book (P/B): 1.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.01
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 0.91
• Enterprise Value/Gross Profit: 4.36
• Enterprise Value/Ebitda: 4.35
• 1Y Price Target: $95.25
• Price Target Upside: 73.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 19

• Rating: 71 Outperform
• Price Target: $64.00 ▲(16.43%Upside)

BioMarin's overall stock score reflects strong financial performance and positive earnings call sentiment as the most significant factors. Technical analysis indicates current market weakness, while valuation suggests a fair price relative to earnings. Strategic growth initiatives and global revenue diversification buffer against market uncertainties.

Positive Factors

Business Strategy

BioMarin's recent deal with Inozyme is seen as a capital-efficient way to scale the ERT business, supporting the company's potential for diversification and growth.

Drug Development

BioMarin has the potential for long-term competitiveness with the development of its own once-weekly drug, BMN333, for achondroplasia.

Market Position

The analyst maintains a Buy rating for BioMarin, suggesting confidence in the company's future potential.

Negative Factors

Clinical Concerns

Concerns that BMRN raised during their earnings call, namely durability of effects and potential of hGH-associated longer-term side effects, are still valid.

Competition

Voxzogo faces potential competitive headwinds from Ascendis' TransCon CNP, which could lead to patient switches as the drug secures approval in various countries.

Market Share

A quarter of Voxzogo-treated patients could switch to TransCon CNP, which poses a risk to maintaining Voxzogo's patient base.

BioMarin Pharmaceutical Business Overview & Revenue Model

Company Description

BioMarin Pharmaceutical Inc. is a biotechnology company that specializes in developing and commercializing innovative biopharmaceuticals for serious and life-threatening rare genetic diseases. Headquartered in San Rafael, California, BioMarin operates within the healthcare and biotechnology sectors, focusing on enzyme replacement therapies and gene therapies. Its core products include treatments for conditions such as phenylketonuria (PKU), mucopolysaccharidosis (MPS) disorders, and achondroplasia.

How the Company Makes Money

BioMarin Pharmaceutical makes money primarily through the sale of its proprietary biopharmaceutical products. The company's revenue streams are driven by the commercialization of its approved therapies, which are often high-priced due to their specificity and effectiveness in treating rare diseases. Key revenue-generating products include Vimizim, Naglazyme, and Palynziq, among others. Additionally, BioMarin invests in research and development to expand its product pipeline, which could lead to future revenue opportunities. The company also engages in strategic partnerships and collaborations with other pharmaceutical firms and research institutions to enhance its product offerings and market reach, contributing to its earnings.

BioMarin Pharmaceutical Financial Statement Overview

Summary

BioMarin demonstrates strong financial performance with significant revenue growth, improved profit margins, and robust cash flow management. The financial stability is highlighted by a low debt-to-equity ratio and strong equity financing, although debt levels need monitoring.

Income Statement

BioMarin Pharmaceutical has demonstrated a robust financial performance with strong revenue growth, rising from $2.09 billion in 2022 to $2.93 billion TTM (Trailing-Twelve-Months). The gross profit margin remains healthy, supported by efficient cost management. The net profit margin and EBIT margins have also shown significant improvement, indicating enhanced profitability. The consistent EBITDA margin growth highlights operational efficiency gains.

Balance Sheet

The company's balance sheet is strong, characterized by a low debt-to-equity ratio, suggesting prudent financial leverage. The equity ratio is impressive, indicating a high level of asset financing through equity. The return on equity has improved substantially, showcasing the company's ability to generate profits from shareholders' investments. However, the company should continue monitoring its debt levels to maintain financial flexibility.

Cash Flow

BioMarin Pharmaceutical has demonstrated strong cash flow dynamics with significant growth in free cash flow, reflecting effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating robust cash generation capabilities. The improved free cash flow to net income ratio further underscores the company's solid cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.94B	2.85B	2.42B	2.10B	1.85B	1.86B
Gross Profit	2.32B	2.27B	1.84B	1.61B	1.38B	1.34B
EBITDA	738.30M	650.86M	310.28M	267.51M	48.03M	-5.85M
Net Income	523.88M	426.86M	167.65M	141.56M	-64.08M	854.03M
Balance Sheet
Total Assets	7.15B	6.99B	6.84B	6.38B	6.00B	5.85B
Cash, Cash Equivalents and Short-Term Investments	1.27B	1.14B	1.07B	1.29B	1.01B	1.07B
Total Debt	595.65M	602.71M	1.10B	1.08B	1.08B	1.08B
Total Liabilities	1.35B	1.33B	1.89B	1.77B	1.73B	1.74B
Stockholders Equity	5.79B	5.66B	4.95B	4.60B	4.27B	4.11B
Cash Flow
Free Cash Flow	620.18M	475.42M	51.65M	44.36M	185.31M	-52.15M
Operating Cash Flow	700.26M	572.84M	159.26M	175.90M	304.54M	85.36M
Investing Cash Flow	122.49M	136.49M	-111.24M	-20.03M	-366.31M	-53.62M
Financing Cash Flow	-522.43M	-526.45M	-18.73M	-18.65M	-48.00K	181.12M

BioMarin Pharmaceutical Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 54.97
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRN, the sentiment is Neutral. The current price of 54.97 is below the 20-day moving average (MA) of 55.73, below the 50-day MA of 58.36, and below the 200-day MA of 64.86, indicating a neutral trend. The MACD of -0.98 indicates Negative momentum. The RSI at 48.66 is Neutral, neither overbought nor oversold. The STOCH value of 61.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRN.

BioMarin Pharmaceutical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	84 Outperform	$11.91B	20.00	30.22%	―	24.49%	244.87%
GMAB	78 Outperform	$12.72B	11.60	22.69%	―	25.11%	46.46%
UTHR	76 Outperform	$12.82B	11.47	19.94%	―	19.85%	21.16%
INCY	74 Outperform	$13.23B	210.71	0.47%	―	17.13%	-88.78%
BMRN	71 Outperform	$10.58B	20.40	9.64%	―	17.99%	152.10%
ASND	52 Neutral	$10.40B	―	357.68%	―	10.69%	34.71%
Sector *	51 Neutral	$7.44B	0.40	-61.90%	2.33%	17.14%	1.55%

BioMarin Pharmaceutical Corporate Events

BioMarin Pharmaceutical Approves Equity Plan Amendment

On May 20, 2025, BioMarin Pharmaceutical Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 8,000,000. This amendment, effective immediately, was previously approved by the Compensation Committee, indicating strong internal support for expanding equity incentives. Additionally, stockholders elected ten directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation, reflecting continued confidence in the company’s leadership and strategic direction.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

BioMarin Acquires Inozyme Pharma for $270 Million

On May 16, 2025, BioMarin Pharmaceutical Inc. announced an agreement to acquire Inozyme Pharma, Inc. for approximately $270 million. This acquisition aims to enhance BioMarin’s enzyme therapy portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, a rare genetic condition. The transaction is expected to close in the third quarter of 2025, pending regulatory approval and other conditions. The acquisition is strategically significant for BioMarin, as it aligns with their commitment to advancing treatments for serious genetic conditions, potentially offering the first treatment for ENPP1 Deficiency. The first pivotal data readout for INZ-701 in children is anticipated in early 2026, with a potential launch in 2027, marking a significant step forward in addressing unmet medical needs.

The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.